TREATMENT OF SCHIZOPHRENIA IN ELDERLY PATIENTS

Introduction: The treatment of schizophrenia in elderly patients presents a significant clinical challenge due to the disease's particularities in this age group. Schizophrenia is a chronic mental disorder characterized by profound disturbances in thought, emotions, and behavior. In elderly patients, the condition may manifest in a more complex manner, with exacerbation of psychotic symptoms and cognitive decline that negatively impacts quality of life. The interplay between aging and schizophrenia requires a therapeutic approach tailored to the specific needs of the elderly, considering comorbidities, polypharmacy, and adverse effects of treatments. Objective: The objective of the systematic review was to evaluate treatment strategies for schizophrenia in elderly patients, examining the effectiveness and safety of available therapeutic interventions, as well as the specific clinical management issues within this population. Methodology: The systematic review was conducted based on the PRISMA checklist, utilizing the databases PubMed, Scielo, and Web of Science. Five main descriptors were used: "schizophrenia," "elderly," "treatment," "antipsychotic therapy," and "effectiveness." Articles published in the last 10 years were included. Inclusion criteria were: studies focused on patients aged 65 and older diagnosed with schizophrenia, articles addressing specific therapeutic interventions, and studies reporting quantifiable clinical outcomes. Exclusion criteria were: articles that did not differentiate the age group of participants, studies without original data or that did not include elderly patients, and publications that did not directly address schizophrenia treatment. Results: The results indicated that treatment for schizophrenia in the elderly frequently involved the use of atypical antipsychotics, which are preferred due to their more favorable side effect profile compared to typical antipsychotics. However, the effectiveness of these medications may be reduced in the elderly due to altered pharmacokinetics and increased risk of adverse effects. The combination of psychosocial therapy and support proved beneficial in improving treatment adherence and quality of life for patients. The need for individualized management and consideration of comorbidities were also highlighted. Conclusion: Treatment of schizophrenia in elderly patients requires a personalized approach that accounts for the complexities associated with aging. Medication choices should be made cautiously, prioritizing those with a lower risk of adverse effects. Additionally, integrating psychosocial strategies can significantly improve clinical outcomes and quality of life for these patients. Ongoing review of practices and guidelines is crucial for optimizing care and addressing the needs of this aging population.